Compare OVBC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | MGNX |
|---|---|---|
| Founded | 1872 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 220.6M |
| IPO Year | 1996 | 2013 |
| Metric | OVBC | MGNX |
|---|---|---|
| Price | $48.15 | $3.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 28.6K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | $52.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.51 | $1.19 |
| 52 Week High | $50.68 | $4.64 |
| Indicator | OVBC | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 49.67 |
| Support Level | $44.63 | $1.49 |
| Resistance Level | $50.68 | $4.64 |
| Average True Range (ATR) | 1.34 | 0.27 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 62.62 | 2.60 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.